Nama's AI scorecard currently rates Guardian Pharmacy Services Buy (6.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is GRDN's P/E ratio?

Guardian Pharmacy Services trades at a trailing price-to-earnings ratio of 33.1.

When does GRDN report earnings?

Guardian Pharmacy Services's next scheduled report is on Mar 11, 2027. Analysts expect EPS of $0.41.

What is the GRDN price target?

The median analyst price target from 7 analysts is $50.00, with a range of $47.00 – $52.00.

Is GRDN Shariah compliant?

Nama's AAOIFI-style screen reads Guardian Pharmacy Services as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Guardian Pharmacy Services (GRDN)

Healthcare · Medical Care Facilities · NYSE

Guardian Pharmacy Services (GRDN) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $2.69B, a trailing price-to-earnings ratio of 33.1 and a free-cash-flow yield of 3.0%. Over the most recent reported fiscal year, revenue grew 17.9% and free cash flow per share grew 90.1%. Nama's AI scorecard rates it Buy, 6.4 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 6.4/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Leading · +42.8% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-12.3%

How far the last close sits under the highest price of the past five years.

Market cap	$2.69B
Trailing P/E	33.1
Price / book	10.9
Price / sales	1.8
FCF yield	3.0%
Dividend yield	—
Gross margin	21.6%
Operating margin	5.8%
Net margin	4.5%
Revenue growth (YoY)	+17.9%
Revenue growth (3-yr annual)	+16.8%
EPS growth (YoY)	—
FCF/share growth (YoY)	+90.1%
Beta	0.0
Exchange	NYSE
Sector	Healthcare
Industry	Medical Care Facilities

GRDN earnings

Next report: Mar 11, 2027 (Q4 2026, EPS estimate $0.41). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.33	$0.31	+6.5%	—
Q2 2026	Aug 6, 2026	$0.29	$0.27	+7.4%	$351.77M
Q1 2026	May 6, 2026	$0.29	$0.24	+20.8%	$336.60M
Q4 2025	Mar 11, 2026	$0.37	$0.27	+37.0%	$397.62M

GRDN analyst price target

Median target $50.00 from 7 analysts, ranging $47.00 – $52.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live GRDN data on Nama Insights →

GRDN FAQ

Is GRDN a buy?: Nama's AI scorecard currently rates Guardian Pharmacy Services Buy (6.4 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is GRDN's P/E ratio?: Guardian Pharmacy Services trades at a trailing price-to-earnings ratio of 33.1.
When does GRDN report earnings?: Guardian Pharmacy Services's next scheduled report is on Mar 11, 2027. Analysts expect EPS of $0.41.
What is the GRDN price target?: The median analyst price target from 7 analysts is $50.00, with a range of $47.00 – $52.00.
Is GRDN Shariah compliant?: Nama's AAOIFI-style screen reads Guardian Pharmacy Services as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.